Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab Shows Early Promise in DSRCT

April 29th 2021

Intraperitoneal radioimmunotherapy with the anti-B7H3 murine monoclonal antibody 131I-omburtamab was well tolerated with low radiation exposure to normal organs, making it a feasible option to combine with other therapies in patients with desmoplastic small round cell tumor.

Observation May Be Preferrable to Surgery in Certain Cases of Desmoid Tumor Fibromatosis

April 29th 2021

The local recurrence rate after surgical excision was similar to the rate of progression with active surveillance in patients with extra-abdominal desmoid tumor fibromatosis, suggesting that observation may be sufficient in some cases.

Dr. Gorlick on the Potential of ADCs in Osteosarcoma

April 20th 2021

Richard Gorlick, MD, discusses the potential of antibody-drug conjugates in patients with osteosarcoma.

Selinexor Improves QoL in Advanced Unresectable Dedifferentiated Liposarcoma

April 19th 2021

Selinexor resulted in lower rates and slower worsening of pain in patients with advanced unresectable dedifferentiated liposarcoma vs placebo, and may represent a novel option to provide convenience, improved adherence, and reduced caregiver burden vs existing parenteral therapies.

Making the Choice: Osseus Reattachment of the Greater Trochanter Vs Soft Tissue–Only Abductor Repair in Bone Cancers

April 16th 2021

Reattaching the greater trochanter to the proximal femur endoprosthesis did not show an improvement in Trendelburg gait or reliance on an assistive ambulatory device vs a soft tissue–only abductor repair in patients with bone cancers.

Dr. Gorlick on Methods for Identifying Immunotherapeutic Targets in Osteosarcomas

April 15th 2021

Richard Gorlick, MD, highlights methods for identifying immunotherapeutic targets in osteosarcomas.

Dr. Subbiah on the Efficacy of Selpercatinib in RET Fusion–Positive Cancers

April 13th 2021

Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.

Dr. Gorlick on the Use of Integrative Surfaceome Profiling to Identify Targets in Osteosarcomas

April 12th 2021

Richard Gorlick, MD, discussed results from a study examining the use of integrative surfaceome profiling to identify immunotherapeutic targets in patients with osteosarcomas.

Dr. Trent on the Role of Avapritinib in PDGFRA Exon 18+ GIST

April 9th 2021

Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.

Dr. Murphy on Remaining Questions With SBRT in Pediatric Sarcoma

April 8th 2021

Erin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.

Clinical Benefit of Ripretinib Expands as Investigators Consider Future Directions

April 8th 2021

Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.

Dr. Murphy on the Clinical Implications of Pazopanib Plus SBRT in Pediatric Sarcoma

April 7th 2021

Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.

Dr. Murphy on Future Research Efforts With Pazopanib Plus SBRT in Pediatric Sarcoma

April 6th 2021

Erin Murphy, MD, discusses future research efforts with pazopanib plus stereotactic body radiation therapy in patients with pediatric sarcoma.

Dr. Wagner on the Rationale for Immunotherapy in Angiosarcoma

April 5th 2021

Michael Wagner, MD, discusses the rationale for using immunotherapy in the treatment of patients with angiosarcoma.

FDA Grants Fast Track Status to Annamycin for Soft Tissue Sarcoma Lung Metastases

March 30th 2021

The FDA has granted a fast track designation for annamycin as a treatment for patients with soft tissue sarcoma lung metastases.

Dr. Trent on the Utility of ctDNA to Understand Primary Mutations in GIST

March 19th 2021

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

Extremity Sarcoma Trial Utilizes Patient Willingness Outcomes to Gauge Accrual

March 19th 2021

Most patients with extremity sarcoma are willing to participate in a randomized clinical trial exploring various postoperative cancer surveillance regimens.

Presence of Pathogenic Variants Provide Rationale for Germline Sequencing in Pediatric Rhabdomyosarcoma

March 3rd 2021

Pathogenic germline variants identified among children and young adults with rhabdomyosarcoma suggest that all children with RMS should undergo germline sequencing to utilize available surveillance guidelines and inform potential gene-specific therapy options.

Dr. Wagner on the Safety Profile of Nivolumab/Ipilimumab in Angiosarcoma

March 2nd 2021

Michael Wagner, MD, discusses the safety profile of nivolumab plus ipilimumab in patients with angiosarcoma.

Dr. Trent on the Need for Novel Combination Strategies in Metastatic GIST

February 24th 2021

Jonathan C. Trent, MD, PhD, discusses the need to develop novel combination strategies for the treatment of patients with metastatic gastrointestinal stromal tumors.